期刊文献+

Bevacizumab辅助治疗新生血管性青光眼 被引量:4

Intravitreal Becacizumab treatment the neovascular glaucoma as an adjunct method
暂未订购
导出
摘要 目的:观察玻璃体腔注射bevacizumab(intravitreal bevacizumab,IVB),联合玻璃体切除、视网膜光凝+小梁切除术治疗新生血管性青光眼(neovascular glaucoma,NVG)临床疗效。方法:对2007-06/2009-06在我院眼科收治由于视网膜中央静脉阻塞(缺血型)继发新生血管性青光眼患者27例27眼,角膜缘后3.5mm玻璃体腔注射bevacizumab0.05mL/1.25mg,治疗后7d进行玻璃体切除、视网膜光凝+小梁切除。术后随访12mo,观察视力、虹膜及房角新生血管及眼压情况。结果:IVB 7d后,25眼虹膜表面、房角新生血管消失(93%)。2眼新生血管明显变细,但未完全消退(7%)。IVB治疗前平均眼压(55.81±4.65)mmHg,治疗后7d平均眼压(42.07±7.49)mmHg,两者眼压比较虽然差异有显著性(t=14.973,P<0.01),但局部应用降眼压药后眼压仍高于正常范围(28~50)mmHg。玻璃体切除、视网膜光凝+小梁切除术后1,3,6,9,12mo,平均眼压分别为(14.85±4.56;16.70±3.73;20.04±6.58;19.30±4.74;19.67±4.12)mmHg,与IVB后7d平均眼压比较差异均有显著性(P<0.01)。手术后眼压控制完全成功22眼(82%),部分成功3眼(11%),眼压未控制2眼(7%)。27眼视力均保持稳定或稍有增进。结论:IVB辅助手术治疗NVG,可以促进虹膜、房角、视网膜新生血管迅速消退,有效的控制眼压,降低手术并发症,提高了手术的成功率,同时进行原发病的治疗远期效果明显提高。 AIM: To observe the clinical effect of the intravitreal bevacizumab ( IVB ) combined with vitrectomy, retinal photocoagulation and trabeculectomy as a mult-treatment for the neovascular glaucoma(NVG). METHODS: Totally 27 patients 27 eyes which had the NVG secondary from central retinal vein occlusion(CRVO) were enrolled. All eyes accepted the vitrectomy, retinal photocoagulation combined with trabeculectomy 7 days after IVB (0. 05mL/l. 25mg). The visual acuity, the condition of the new vessels on the iris and the angle of anterior chamber and the intraocular pressure (lOP) were observed 12 months postoperatively. RESULTS: The new vessels on the iris and the angle of anterior chamber regressed completely in 25 eyes(93%), 7 days after IVB and thinned obviously in 2 eyes but not regressed(7% ). The mean lOP before the IVB (55.81 ±4. 65mmHg) and the after (42, 07 ± 7.49mmHg) had significant difference( t = 14. 973, P 〈 0.01 ), but still higher than normal level (28-50mmHg). The mean lOP 1 month, 3, 6, 9 and 12 months after the vitrectomy, retinal photocoagulation and trabeculectomy (14.85±4.56 , 16.70 ±3.73, 20. 04 ± 6.58, 19.30± 4.74, 19.67 ± 4.12, respectively) mmHg and 7 days after IVB had significant difference ( P〈 0.01 ). The lOP were controlled completely in 22 eyes (82%), partly controlled in 3 eyes (11%), and not controlled in 2 eyes (7%). The visual acuity of all the eyes was stable and rise slightly. CONCLUSION : IVB as an adjunct method combined with vitrectomy, retinal photocoagulation and trabeculectomy can make the new vessels on the iris and the angle of anterior chamber regression and to lower the IOP, thus it can increase the achievement ratio of the operation and decrease the complication. And the long-term effect is better to cure the protopathy at the same time.
出处 《国际眼科杂志》 CAS 2010年第10期1903-1905,共3页 International Eye Science
基金 中国陕西省科技攻关基金资助项目(No.2008K01-40)~~
关键词 Bevacizumab玻璃体内注射 玻璃体手术 滤过术 视网膜光凝 新生血管性青光眼 bevacizumab IVB vitrectomy trabeculectomy retinal photocoagulation neovascular glaucoma
  • 相关文献

参考文献3

二级参考文献30

  • 1秦梅,陈大本.全视网膜冷冻、小梁切除及巩膜条引流术治疗新生血管性青光眼[J].中国实用眼科杂志,1995,13(9):557-558. 被引量:5
  • 2马立,赵本严,狄雅芬.前部视网膜冷凝联合小梁切除术治疗新生血管性青光眼[J].中华眼科杂志,1996,32(2):118-122. 被引量:21
  • 3[2]Fernandez VJ,Castro J,Cordido M,et al.Treatment of diabetic neovascular glaucoma by panretinal ablation and trabeculacomy.Acta Ophthalmol (Copenh),1988,56:612~615
  • 4[5]Tauber J.New clinical classification for iris neovascularization.Ophthalmology,1987,95:542~546
  • 5[6]Jaeson VL.Am J Ophthalmol 1977,83:508~511
  • 6[7]Curtin VT,Fujin OT,Norton EWD,et al.Comparative histopathology of cryosurgery and photocoagulation.Arch Ophthalmol,1966,75:674~677
  • 7[8]Mohan V,Eagling EM.Peripheral retinal cryotheropy as a treatment for neovascular glaucoma.Trans Ophthalmol Soc OK,1978,78:93~97
  • 8Psichias A, Bartz Schmidt KU, Thumann G, et al. Vitreoretinal surgery in the treatment of neovascular glaucoma. Klin Monatsbl Augenheilkd, 1999,214:61-70.
  • 9Hajji Z, Rouillot JS, Roth P, et al. Should associated intraoperative and/or postoperative photocoagulation be systematic during or after vitrectomy for proliferative diabetic vitreoretinopathy? J Fr Ophthalmol, 2003, 26:47-53.
  • 10Lloyd MA, Heuer DK, Baerveldt G, et al. Combined Molteno implantation and pars plana vitrectomy for neovascular glaucomas.Ophthalmology, 1991, 98:1401-5.

共引文献60

同被引文献30

  • 1孙兴怀.难治性青光眼的治疗[J].国外医学(眼科学分册),1995,19(1):26-31. 被引量:203
  • 2李桥,王育良,高卫萍.Ahmed青光眼阀植入术治疗难治性青光眼的临床观察[J].临床眼科杂志,2006,14(2):118-120. 被引量:11
  • 3Lin P, WoUestein G, Glavas IP, et al. Contact transscle- ral neodymium: yttrium-aluminum-garnet laser cyclophoto coagulation long-term outcome. Ophthalmology, 2004, 111:2137 - 2143.
  • 4Polrak Z, Cohen T, Neufeld G. The VEGF splice vari- ants: properties, receptors, and usage for the treatment of ischemic diseases. Herz, 2000, 25:126 - 129.
  • 5Macarie S, Palko Z. Therapeutic difficulties in neovascular glaucoma. Oftalmologia, 2006, 50:73 - 76.
  • 6Cohen AF, Van Bronswijk H. New medications; be- vaeizumab. Ned Tijdschr Geneeskd, 2006, 150:2194 -2195.
  • 7Shahin Yazdani, MD. Intravitreal Bevacizumab (Avastin) injection for neovascular glaucoma. Glaucoma, 2007, 16: 437 - 439.
  • 8Vatavuk Z, Bencic G, Mandic Z. Intravitreal bevacizumab for neovascula r glaucoma follow ing central retinal artery occlusion. Eur J Ophthalmol, 2007, 17:269 - 271.
  • 9Vatavuk Z, Beneic G, Mandic Z. Intravitreal bevacizumab for neovascular glaucoma following central retinal artery occlusion. Eur J Ophthalmol, 2007, 17:269 - 271.
  • 10Ryoo NK, Lee EJ, Kim TW. Regression of iris neovascularization after subconjunctival injection of bevacizumab. Korean J Ophthalmol 2013; 27(4):299-303.

引证文献4

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部